secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0001104659-24-068503
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent BioPharma enters ADC collaboration with Alphamab; milestones up to $615.5M
--------------------------------------------------------------------------------

- Collaboration to discover, develop, and commercialize novel antibody drug conjugates (ADCs) for cancers.
- Total upfront and milestone payments to Alphamab up to $615.5 million plus tiered sales royalties.
- ArriVent gains exclusive rights to develop and commercialize ADCs outside greater China; Alphamab retains greater China rights.
- Deal leverages Alphamab's proprietary linker-payload platform and glycan-conjugation technology.
- ArriVent CEO Bing Yao cites potential to add multiple innovative ADC programs to pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465924068503/0001104659-24-068503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465924068503/tm2416477d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-068503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer